MSB 2.17% $1.13 mesoblast limited

Ann: DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial, page-322

  1. 2,024 Posts.
    lightbulb Created with Sketch. 315
    Apply flexible band to that......remember it was September...then November, now your touting December? Timelines slip and slip, surely priority to regain face and investor confidence first and foremost is get the Type A inked in.....mid November.
    Steps after that can take there own course, shorts may have a different view but I think they might be betting on a rejection for the meeting...gutsy but not without some merit given the surprise "news" of late both pre-ODAC and post FDA.....quite a firewalk so far.
    Market completely non plussed by ARDS P3 trial update, even with the Covid factor the company cannot sway the market makers.
    GLTAH I for 1 cannot compare it to any Stockmarket experience so far...yet I remain very interested.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.13
Change
-0.025(2.17%)
Mkt cap ! $1.284B
Open High Low Value Volume
$1.15 $1.16 $1.11 $7.363M 6.488M

Buyers (Bids)

No. Vol. Price($)
5 94863 $1.13
 

Sellers (Offers)

Price($) Vol. No.
$1.13 5000 2
View Market Depth
Last trade - 16.10pm 26/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.